Journal
TRANSLATIONAL ANDROLOGY AND UROLOGY
Volume 7, Issue 5, Pages 831-843Publisher
AME PUBL CO
DOI: 10.21037/tau.2018.08.03
Keywords
Positron emission tomography/computed tomography (PET/CT); nuclear medicine; prostatic neoplasms; tomography; emission-computed, single-photon; gallium
Categories
Funding
- Intramural Research Program of the National Institutes of Health
- National Cancer Institute, National Institutes of Health [HHSN261200800001E]
- NATIONAL CANCER INSTITUTE [ZIABC010655] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) is an emerging prostate cancer imaging method, which has been reported to have a higher sensitivity and specificity than the currently approved PET imaging agents. Multiple PSMA ligands are being investigated around the world and applications range from primary tumor characterization, to local staging, biochemical recurrence, metastasis, and image-guided interventions. The most investigated PET tracers are labelled with 68-Gallium or 18-Fluoride and are discussed in this review. Additionally, Tc-99m labeled PSMA agents for single photon emission computed tomography (SPECT) imaging are elucidated as an alternative method of PSMA image acquisition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available